Drugmakers call for additional premiums from Russian government during public procurements

4 October 2017

Russian and global pharmaceutical companies operating active substances’ production in Russia want to receive a premium of 40% of the value of the public procurements contracts signed with the Russian government, according to recent statements by Veronika Skvortsova, Russia’s Minister of Health, reports The Pharma Letter’s local correspondent.

Vikram Punia, president of Pharmsynthez (MICEX: LIFE), one of Russia’s leading drugmakers, said the company supports this proposal, noting that, if these 40% premiums are introduced, Pharmsynthez will be ready to invest more than 10 billion roubles ($174 million) in the production of substances in Russia.

The same position is shared by Dmitry Morozov, chief executive of Biocad, another leading Russian drugmaker, who said he supports the introduction of a 40% price premium since this can increase the investment attractiveness of the entire Russian pharmaceutical industry.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK